Malta Offers Free Entresto Access to 4,000 Heart Failure Patients

Why This Matters

Entering a final stretch of treatment options for chronic heart failure in Malta has just became faster and free. The Malta Ministry of Health has green-lit a shift that removes barriers to a therapy thousands of local patients have struggled to afford: sacubitril/valsartan (Entresto), now available without cost to eligible residents through the public pharmacy network.

• ~4,000 people will access Entresto immediately at zero out-of-pocket cost; roughly half of Malta's heart failure population gains a clinically proven tool previously available only through private spending.

• €6M annual commitment positions this move as one of the most significant cardiovascular investments the health system has made in years.

• Rollout begins immediately and will proceed gradually—those currently taking older heart medications should confirm with their cardiologist if Entresto is appropriate for their clinical situation before any transition occurs.

A Decade-Long Wait Ends

Malta joins the circle of European health systems backing this medication, but notably arrives late. Scotland's National Health Service reimbursed Entresto in March 2016. Germany approved it in November 2015. Ireland followed in December 2017. Over this span, Swedish patients gained access in April 2016, French health authorities documented benefit in 2018, and Dutch health economists confirmed cost-effectiveness by 2019.

The delay cost lives. Between 2007 and 2017, one in two Maltese heart failure patients never received standard ACE inhibitors or angiotensin receptor blockers, and nearly three-quarters missed critical medications like beta-blockers—drugs recommended internationally for over two decades. Those gaps persisted partly because newer options remained trapped behind private pricing. By 2020, non-compliance figures had improved to 25%, but the damage already compounded: Malta maintains one of the European Union's highest rates of preventable heart failure hospital admissions. When someone stabilizes on the right medication, they avoid the emergency ward. When they don't, they cycle through Mater Dei Hospital's intensive care repeatedly, driving costs and risks upward.

How Entresto Actually Works

The drug combines two molecules: sacubitril, which enhances the heart's natural protective pathways, and valsartan, which blocks harmful neurohormonal signals. Together, they lighten the workload on a failing heart muscle. Think of it as removing a brake and adding a cushion simultaneously.

The PARADIGM-HF trial, which involved over 8,000 patients across 47 nations, set the evidence standard. Compared to enalapril—an older ACE inhibitor used for decades—sacubitril/valsartan reduced the combined risk of cardiovascular death or hospitalization by 20%. All-cause mortality dropped 16%. Patients reported breathing easier and tolerating exertion better within the first month. These weren't marginal gains; they represented the most substantial leap in heart failure treatment effectiveness since beta-blockers entered routine use in the 1990s.

Real-world data from Sweden confirmed the message: 82% of patients remained on the medication at one year, suggesting it is tolerated well in clinical practice. Ireland documented that annual usage climbed from 1,186 patients in November 2018 to 5,519 by November 2022—a rate acceleration that reflects both physician confidence and patient need.

The Burden Growing, Not Shrinking

Heart disease kills more Maltese people than any other condition. In 2023, cardiovascular disease accounted for 28% of all deaths (1,168 fatalities), with 384 of those from conditions like heart failure. That proportion hasn't budged materially in a decade. What has changed is the forecast: a January 2024 national projection warned that heart failure incidence could nearly double by 2040 if prevention and treatment trajectories don't shift sharply upward.

Specifically, heart failure with reduced ejection fraction—the precise category Entresto targets—is projected to climb almost 50% by 2040, reaching 5.2 cases per 1,000 residents aged 50 and older. In absolute terms, that means thousands more Maltese will face breathlessness, fatigue, and risk of sudden death unless medication access and adherence improve now.

The Mater Dei Heart Failure Clinic operates near capacity. A 2024 study conducted at Mater Dei by pharmacists showed that structured discharge planning and post-hospitalization coordination could reduce unplanned readmissions by 12.3% within 30 days—a meaningful reduction. Yet that benefit vanished by 60 days, signalling that coordination alone is insufficient. Patients need the right drug in hand, consistently refilled, without financial friction. That's where Entresto's arrival in the free-to-all scheme matters tangibly.

Who Qualifies, and What to Expect

Entresto reaches residents aged one year and older. Children, adolescents, and adults with symptomatic heart failure and left ventricular ejection fraction below 40%—a measurement of how efficiently the heart pumps—form the target population. Available in three dose strengths, the medication allows titration matched to each patient's blood pressure, kidney function, and symptom trajectory.

Contraindications exist: a history of angioedema (a rare but serious allergic swelling), severe liver disease, pregnancy, and use of ACE inhibitors within 36 hours of Entresto initiation. The most frequent side effect is low blood pressure, occurring more often than with older drugs—generally manageable by reducing the dose. Conversely, Entresto triggers less cough, less potassium elevation, and less kidney stress than traditional ACE inhibitors, a meaningful trade-off for patients who previously abandoned therapy due to unpleasant effects.

Baseline tests—kidney and liver function, blood work—precede initiation. During dose adjustment, blood pressure monitoring becomes routine. Prescribers must confirm that current heart medications (typically a beta-blocker, an older ACE inhibitor or ARB, and a diuretic) are already optimized before switching.

What the €6M Investment Covers

Annual cost to the Malta national healthcare budget: €6M. Per-patient annual cost: approximately €1,500. That expense sits within the €400M the country allocates annually to all publicly funded medicines, with cardiovascular drugs representing a major therapeutic category historically. Measured against averted hospitalizations, the math tilts favourable. Dutch health economists calculated that every €1 spent on sacubitril/valsartan averted €1.40 in acute-care costs within three years, primarily through fewer intensive-care admissions and shortened hospital stays. Germany's health technology assessment body concluded positive effects on mortality and quality of life substantially outweighed hypotension concerns.

Yet equity concerns loom. The scheme reaches 4,000 patients; Malta harbors approximately 8,000 with heart failure. Half remain excluded—some with preserved ejection fraction (a different disease category), others undiagnosed or undertested, particularly older residents and those without recent medical evaluation. Closing that diagnostic gap demands expanded screening in primary care and cardiology clinic activity beyond prescribing. Health Minister Jo Etienne Abela has framed Entresto's addition as part of a broader system-strengthening effort, though specific plans for earlier detection remain unstated.

The Launch and What Comes Next

Dispensing occurs through the Pharmacy-Of-Your-Choice (POYC) network, which already provides free chronic-condition medications including empagliflozin (Jardiance), a diabetes and heart disease dual-benefit agent introduced recently. The rollout "will proceed gradually and in a monitored manner," according to the ministry, signalling that patients currently stable on older medications will not face sudden switching. Cardiologists and general practitioners will drive eligibility assessment and initiation, so residents should raise the topic during routine appointments if heart failure and reduced ejection fraction apply to their situation.

The delayed adoption—a decade behind Germany and almost a decade behind Scotland—reflects broader patterns in Maltese healthcare adoption timelines. Gazing forward, questions persist: Will newer agents like SGLT2 inhibitors for preserved-ejection-fraction heart failure or vericiguat for post-hospitalization decompensation follow on an accelerated track? Will targeted outreach close the diagnostic gap among older and undertested populations? Will primary-care training expand to recognize early heart failure signals?

For now, the practical step is transparent: if you or a family member has received a heart failure diagnosis with reduced ejection fraction and continues to experience shortness of breath or fatigue despite medications, initiate a conversation with your cardiologist about POYC eligibility. Entresto represents not a cure—heart failure remains a chronic condition requiring lifelong management—but a clinically robust means to extend life, reduce hospitalizations, and restore functional capacity. In a health system perpetually stretched thin, that distinction matters profoundly.

Expanding cardiac rehabilitation programmes and a telemedicine initiative targeting follow-up care in Gozo signal parallel investments aimed at closing care gaps. Combined with broader Entresto and empagliflozin access, these measures may finally reverse the upward hospitalisation curve among Malta's heart failure population—a benchmark that has resisted improvement for too long.